Date: 2012-06-29
Type of information: Capital increase
Company: Galapagos (Belgium)
Investors: Galapagos\' employees
Amount:
Funding type: capital increase through warrant exercises
Planned used:
Others: Galapagos, the belgian mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action, announced today a capital increase arising from employee warrant exercises. Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period from 9 June 2012 through 22 June 2012, Galapagos issued 18,699 new ordinary shares on 29 June 2012 for a total capital increase (including issuance premium) of €160,253.07. No member of the Board or Executive Committee exercised warrants.
To date, Galapagos\' total share capital amounts to €143,770,414.14; the total number of securities conferring voting rights is 26,577,554, which is also the total number of voting rights (the \"denominator\"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,171,362, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
Therapeutic area: Technology - Services
